Umbilical cord blood pTau217 and BD-tau are associated with markers of neonatal hypoxia: a prospective cohort study

Emma Payne,[1] Fernando Gonzalez-Ortiz,[2,3] Kaitlin Kramer,[4,5] Thomas Payne,[4,5] Shreeya Marathe,[5] Neha Mahajan,[5] Ashly Liu,[5] Jessica Barry,[5] Andrew Duckworth,[5] Mitchell Brookes,[5] Bradley de Vries,[6,7] Benjamin Moran,[8,9] Helen Manning,[10] Adrienne Gordon,[4,6] Kaj Blennow,[2,3] Henrik Zetterberg,[11,12] David Zalcberg,[4,5] Robert D. Sanders[4,5]

Author affiliations:

1. St George Hospital, South Eastern Sydney Local Health District, New South Wales, Australia
2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
3. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
4. Central Clinical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia
5. Department of Anaesthetics, Royal Prince Alfred Hospital, Sydney Local Health District, New South Wales, Australia
6. Sydney Institute for Women, Children and their Babies, Sydney Local Health District, New South Wales, Australia

23 7. NHMRC Clinical Trials Centre, The University of Sydney, New South Wales,
24 Australia
25 8. Critical Care Program, The George Institute of Global Health, Sydney, Australia.
26 9. Department of Intensive Care, Gosford Hospital, Gosford, Australia.
27 10. Dept of Obstetrics and Gynaecology, Central coast local health district, NSW
28 11. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and
29 Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal,
30 Sweden
31 12. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal,
32 Sweden
33
34 * Corresponding authors: Emma Payne, David Zalcberg
35 email: emmapayne4114@gmail.com
36 address: St George Hospital, Gray St, Kogarah, NSW, 2217
37 phone: +61449554114
38 Word Count: 2903
39

Abstract

Objective: Current methods for early detection of hypoxic–ischemic encephalopathy (HIE) are limited by lack of specificity, cost, and time constraints. Blood tau protein concentrations reflect neuropathology in adults. This study examines tau as a potential HIE biomarker in neonates by relating cord blood levels to short-term fetomaternal outcomes. We aimed to examine 1) association of BD-tau with non-reassuring fetal status; 2) correlations between cord blood tau and other hypoxia biomarkers; 3) associations between tau levels and risk factors for fetomaternal morbidity; 4) associations between tau levels and short-term fetomaternal outcome.

Methods: 107 maternal participants were prospectively recruited at Royal Prince Alfred Hospital—a large Australian tertiary referral centre. Simoa analysis detected umbilical cord blood pTau217 and brain-derived (BD)-tau levels.

Results: Of 509 deliveries, cord blood was analysed in 107/110 recruited maternal participants. BD-tau correlated with non-reassuring fetal status (OR=3.0;95%CI=1.6–5.7;p=0.001), though not when adjusting for mode of delivery and gestational age. BD-tau was higher in vaginal deliveries, and positively associated with pTau217, NfL, and lactate ($p<0.001$), and negatively associated with pH and base excess. pTau217 was higher in preterm neonates and was associated with neurofilament light chain (Spearman's rho=0.44,$p<0.001$). BD-tau and pTau217 were associated with maternal hypertension and placental abnormalities.

Conclusions: Cord blood BD-tau correlates with surrogate markers of fetal hypoxia, whilst pTau217 may represent a marker of neurodevelopment. Further studies could explore whether these findings translate to clinical use of tau as an HIE biomarker.

Funding: US National Institutes of Health (grant:R01AG063849-01).

Keywords: tau; asphyxia; hypoxic–ischemic encephalopathy; HIE.

68 # Introduction

69

70 Hypoxic–ischemic encephalopathy (HIE)—a subtype of neonatal encephalopathy—is a
71 syndrome of central nervous system (CNS) dysfunction caused by abnormalities in cerebral
72 blood flow and impaired gas exchange perinatally, resulting in multiple organ failure.[1]
73 Approximately 40–60% of affected infants face mortality or severe neurodevelopmental
74 disability by two years of age.[2]

75

76 Risk factors for HIE can broadly be categorised into antepartum (including fetal and maternal
77 characteristics) and intrapartum factors. Understanding antepartum risk factors can
78 complement intrapartum monitoring techniques used to detect 'non-reassuring fetal status'
79 as defined by pathological fetal heart rate traces and fetal scalp blood sampling. Together,
80 this information can identify fetuses at risk of hypoxic injury and guide decision-making
81 regarding the urgency of delivery. However, intrapartum monitoring techniques are limited
82 by a lack of specificity for pathological neurological damage, measurement difficulties, and
83 poor inter-user reliability.[3,4]

84

85 The only proven neuroprotective treatment for HIE is therapeutic hypothermia (TH), which
86 has only been validated in term or late preterm neonates.[2,5] Severity of HIE can be classified
87 as mild, moderate, or severe based on clinical signs and grading systems such as the
88 modified Sarnat score.[6] However, these scoring criteria are subjective, and grading may fail
89 to identify neonates at risk of long-term adverse neurological sequelae; research has
90 demonstrated abnormal neurological outcome in over 22% of cohorts of mild HIE.[5] At this

91 stage, TH is validated only in moderate to severe HIE, and there is insufficient evidence to
92 recommend TH for mild HIE cohorts.[5] Cord blood biomarkers may be helpful in identifying
93 subgroups of mild HIE who would benefit from TH. Further aids to establish aetiology and
94 severity of HIE include electroencephalogram (EEG) monitoring, and neuroimaging studies
95 including MRI and cranial ultrasound.[3,7] These tools are limited by time and cost constraints,
96 require expert interpretation, and may be difficult to access in emergency situations.[7] This
97 indicates an ongoing need for objective, cost-effective, and rapid measures of identifying HIE
98 in order to appropriately identify subgroups of HIE patients that could benefit from early
99 intervention.
100
101 Real-time physiological biomarkers could address this gap in diagnosis and prognostication
102 by providing objective point-of-care testing. Current cord or whole blood markers such as
103 pH, lactate, and base excess remain non-specific for neurological injury.[2] Tau is a promising
104 biomarker of poor neurological outcome in adult cohorts with acute and chronic
105 neurological disease.[8,9] Studies of tau in neonates has, to date, focused on correlation of
106 total blood tau and cerebral injury-related outcome measures. However, compared to total
107 blood tau, specific tau subtypes—in particular pTau217 and 'brain-derived tau' (BD-tau)—
108 have demonstrated greater specificity for adult neurological injury.[10,11] This is the first study
109 to examine tau subtypes in a neonatal cohort.
110
111 Given the paucity of evidence addressing tau subtypes and fetomaternal outcome, we
112 conducted a prospective cohort study with the following aims:
113 1. Address feasibility of neonatal cord blood tau level measurement in an
114 Australian cohort.

2. Assess the correlation between BD-tau and non-reassuring fetal status.
3. Assess correlations between cord blood tau—BD-tau, pTau217—and other cord blood biomarkers, maternal and neonatal risk factors for encephalopathy, and adverse outcome.

Materials and Methods

Study Population and Design

We performed a prospective cohort study of maternal and neonatal patients at the Royal Prince Alfred Hospital (RPAH), a tertiary referral centre in Sydney, Australia. Maternal participants of any age who were planned to birth at RPAH were eligible for study recruitment. Recruitment occurred prospectively from October 2022 at any time from 4 weeks prior to estimated date of delivery to the immediate post-partum period (with the option of retrospective consent). Trained recruiters obtained written, informed consent in English for all maternal participants in antenatal visits or on the birthing unit. Participants were excluded if they were non-English speaking, or had a history of psychological illness or other conditions that may interfere with capacity to provide informed consent after appropriate counselling in English.

Recruitment was undertaken as part of the BABBies (Benefits of Analysing Brain Biomarkers in perinatal care) Study—a prospective observational cohort study exploring the biomarkers neurofilament light chain (NfL), BD-tau, and pTau217. Data were stored in Sydney Local

138 Health District (SLHD) REDCap electronic database. Ethics approval was obtained from SLHD
139 Research and Ethics Committee (RPAH zone) (approval number: 2022/ETH01100). Our study
140 was performed according to the National Statement on Ethical Conduct in Human Research
141 (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. Data reporting
142 adhered to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
143 guidelines.
144
145 **Cord Blood Collection and Analysis**
146 Umbilical venous cord blood was collected by the attending midwife in the immediate
147 postpartum period. 1–3mL samples were collected and centrifuged in the RPAH Department
148 of Anaesthetics laboratory, and plasma samples were then stored in deidentified cryovials.
149
150 Tau was measured on the Simoa HD-X platform with two-fold dilution factor in plasma.
151 Plasma pTau217 and BD-tau were measured with previously validated assays.[12,13] Signal
152 variations within and between analytical runs were assessed using three internal quality
153 control samples at the beginning and the end of each run.
154
155 **Outcome Data Collection**
156 Demographic and outcome data were collected from RPAH electronic and paper medical
157 records. Mode of delivery was classified categorically: vaginal delivery, emergency caesarean
158 section, and elective caesarean section. Placental abnormalities were defined as any
159 abnormality detected on placental ultrasound, on examination in the birth unit or in the
160 operating theatre, or histopathology. The composite term 'histopathological placental
161 abnormality' refers to only abnormalities detected on anatomical or histopathological

162 examination per the 2014 Amsterdam Working Group nosology for classification of placental
163 clinicopathological disorders.[14] 'Non-reassuring fetal status' was defined as fetal blood
164 sampling showing a pH $\leq$7.20 or lactate >4.7,[15,16] or intrapartum cardiotocography (CTG)
165 changes identified as 'red zone' criteria according to NSW Health electronic fetal monitoring
166 guidelines (Table S1).[17] 'Non-reassuring fetal status' did not include participants incidentally
167 found to have abnormal umbilical cord blood values without meeting other criteria for non-
168 reassuring fetal status.
169

170 **Outcomes**

171 Our primary outcome was the association of BD-tau with non-reassuring fetal status. We
172 adjusted this analysis for gestational age and mode of delivery, given these variables have
173 previously been associated with both non-reassuring fetal status and cord blood
174 concentrations of other biomarkers of acidosis and anaerobic metabolism.[18] Secondary
175 outcomes included the association of BD-tau and pTau217 with antenatal factors
176 (gestational age, head circumference, birthweight), other cord blood biomarkers, maternal
177 factors, delivery factors, and perinatal outcome. Resuscitation at birth was defined as
178 cardiorespiratory support required following drying, warming, and mechanical stimulation.[19]
179

180 **Power Analysis**

181 Our power analysis was based on the association of NfL with non-reassuring fetal status,
182 which is reported separately.[20] We used the previously reported baseline incidence of non-
183 reassuring fetal status of 16%.[15] Based on a two-sided t-test with α=0.025, a sample size of
184 110 participants provides 80% power to detect a Cohen's d of 0.8 (i.e., a large effect size).
185 The power analysis also applies to the primary outcome of this study, with a preserved type

186 1 error rate of α=0.05, as this value was halved a priori for the power calculation to account
187 for additional analysis.
188
189 **Statistical Methods**
190 *Primary outcome*
191 Both BD-tau and pTau217 concentrations showed a strong positive skew, hence were $\log_{10}$-
192 transformed for all analyses. To determine the association of BD-tau with non-reassuring
193 fetal status after adjusting for other variables, we used logistic regression (binomial family
194 with logit link) with maximum likelihood estimation of the model parameters. The
195 parametric G-formula was used to compute the mean risk difference from logistic regression
196 models.[21] We included a BD-tau*mode of delivery interaction in our model, as the
197 relationship between neuronal biomarkers and fetal outcome would likely vary by birth
198 route. To provide interpretable effect measures, we calculated the risk difference for the
199 outcome per increase in BD-tau by its interquartile range (Q3 – Q1). The relative association
200 of cord biomarkers with non-reassuring fetal status was quantified using the area under the
201 receiver operator curve (AUROC). The 95% confidence interval for the AUROC was calculated
202 using 2000 stratified bootstrap replicates.
203
204 *Secondary outcomes*
205 Bivariate biomarker correlations were assessed using rank-based nonparametric methods.
206 The relative strength of biomarker correlations was tested using the method described by
207 Meng, Rosenthal, and Rubin.[22] For continuous secondary outcomes, we used linear
208 regression with the ordinary least squares estimator for the model parameters. Associations
209 between biomarker concentrations and placental abnormalities were adjusted for low birth

weight (defined as birth weight <2.5kg, per World Health Organisation definition).[23] Binary secondary outcomes were tested for linearity, and analysed in the same fashion as our primary outcome.

We used a p-value <0.05 to denote statistical significance. No adjustments for multiple comparisons were made in this preliminary study. All analyses were conducted in R using RStudio (Version 2024.04.0; R Foundation for Statistical Computing, Vienna, Austria). The 'stats' package was used for linear and generalised linear models. The 'cocor' package was used to compare the strength of bivariate biomarker concentrations.[24] The 'plotROC' and 'pROC' packages were used for calculation and plotting of the AUROC.[25]

Results

Over the study period 24th October 2022 to 9th December 2022, 110 maternal study participants were recruited from a total of 509 deliveries at RPAH. Cord blood was collected for a total of 108 participants, of whom 107 had either BD-tau or pTau217 levels available; 105 had BD-tau values and 106 had pTau217 values (STROBE diagram: Figure S1). Cohort demographic information is summarised in Table S2.

Primary outcome

Increased BD-tau was associated with a higher risk of non-reassuring fetal status; each IQR increase in BD-tau was associated with an increased odds of fetal distress (OR=3.0; 95% CI:

233 1.6, 5.7; p=0.001). However, this relationship was no longer observed when adjusting for
234 mode of delivery and gestational age (OR=1.1; 95%CI=0.6, 1.2; p=0.667) (Table S3). BD-tau
235 was not associated with non-reassuring fetal status when stratifying within each individual
236 mode of delivery (Table S3). Comparative performances of BD-tau pH, lactate, and base
237 excess in predicting non-reassuring fetal status are displayed in Figure 1. There was no
238 association demonstrated between pTau217 and non-reassuring fetal status (Wilcoxon
239 p=0.62).
240
241 **Secondary outcomes**
242
243 **Antenatal Factors**
244
245 **Relationship between tau and fetal factors**
246
247 pTau217 was negatively associated with gestational age (Spearman's rho=–0.25, p=0.0096).
248 pTau217 was also negatively associated with birthweight (Spearman's rho=–0.23, p=0.019)
249 and head circumference (Spearman's rho=–0.24, p=0.016), however, these associations were
250 not significant when controlling for gestational age (Table S4). BD-tau did not demonstrate
251 evidence of association with fetal parameters (Figure 2).
252
253 **Relationship between tau and maternal factors**
254
255 A total of 8 participants were classified as having maternal hypertension—either chronic
256 hypertension, gestational hypertension, or pre-eclampsia. Both BD-tau and pTau217 were

257 positively associated with maternal hypertension (median BD-tau: 81.0 vs. 54.9pg/mL,
258 Wilcoxon p=0.026; median pTau217: 10.3 vs. 7.7pg/mL, Wilcoxon p=0.029), but were not
259 associated with other maternal health conditions (Figures S2 and S3).
260
261 **Relationship between tau and intrapartum factors**
262
263 BD-tau was associated with mode of delivery (Kruskal–Wallis p<0.001) (Figure 3), with BD-
264 tau levels being higher with vaginal delivery compared to CS. On pairwise comparisons, no
265 statistically significant difference was detected in BD-tau level between elective and
266 emergency CS (median 48.4 vs. 53.6pg/mL, Wilcoxon p=0.22). pTau217 did not demonstrate
267 a significant association with mode of delivery (Kruskal–Wallis p=.420). pTau217 was
268 negatively associated with the duration of the second stage of labour (Spearman rho –0.4,
269 p=0.042), whilst BD-tau and other biomarkers were not (Figure S4).
270
271 **Correlation between tau and other biomarkers**
272
273 Correlations between cord blood tau and other biomarkers are demonstrated in Figure 4.
274 BD-tau demonstrated a positive association with pTau217 (Spearman's rho=0.66, p<0.001),
275 NfL (Spearman's rho=0.58, p<0.001), and lactate (Spearman's rho=0.34, p<0.001), and a
276 negative association with cord pH (Spearman's rho=–0.29, p=0.003) and base excess
277 (Spearman's rho=–0.35, p<0.001). pTau217 demonstrated a positive correlation with NfL
278 (Spearman's rho=0.44, p<0.001), but was not associated with other biomarkers. We did not
279 observe evidence of a difference between pTau217 and BD-tau in the strength of the
280 positive correlation with NfL (z=1.48, p=0.140) (Table S5).

Relationship between tau and fetoplacental outcome

A total of 11 participants had reported placental abnormalities, 6 of which were defined as histopathological placental abnormalities (Appendix 1). Adjusting for low birth weight, the presence of histopathological placental abnormalities was positively associated with BD-tau and pTau217 (Table S6).

pTau217 levels were associated with preterm birth (median 7.7 in term participants vs. 12.2pg/mL in preterm participants; Wilcoxon p=0.010). In addition, pTau217 levels were positively associated with respiratory complications (median 7.6 vs. 10.4pg/mL; Wilcoxon p=0.012) and resuscitation requirement at birth (median pTau217: 7.6 vs. 10.2pg/mL; Wilcoxon p=0.027), however these associations were not observed when adjusting for preterm birth (Table S7).

Discussion

Main findings

Our study adds credence to the use of cord blood tau as a biomarker of neurodevelopment, perinatal hypoxia, and CNS injury. It is the first to examine associations between fetomaternal outcomes and cord blood subtypes of tau—BD-tau and pTau217. We observed a correlation between BD-tau and surrogate markers of hypoxia, including serum biomarkers

304 of anaerobic metabolism and non-reassuring fetal status. Additionally, we found associations
305 between tau and maternal and fetoplacental factors that could contribute to increased
306 baseline risk of encephalopathy, including preterm birth, placental abnormalities, and
307 maternal hypertension. Understanding the relationship between the pathogenesis of
308 hypoxic brain injury, neuron-specific biomarkers, and clinically observed outcome could aid
309 diagnosis, prognosis, and treatment of patients suffering from HIE.
310

311 Clinical implications and future research

312

313 By addressing surrogate markers of fetal and neonatal hypoxia, our study of predominantly
314 'healthy' participants aims to link blood tau levels with risk factors for HIE, and provide a
315 foundation for future research into the clinical use of cord blood tau in HIE diagnosis. Our
316 study demonstrated a strong correlation between tau levels and non-specific markers of
317 acidosis and anaerobic metabolism, such as neonatal pH and lactate levels, extending
318 previous research.[1,18,26–28] Importantly, our study is the first to examine BD-tau specifically,
319 which offers an advantage over these traditional biomarkers due to its greater specificity for
320 central nervous system (CNS) injury.[18,26–28] Previous studies have mainly involved case-
321 control analyses of HIE cohorts, demonstrating a positive correlation between early serum
322 tau levels, HIE diagnosis based on EEG and clinical criteria, as well as HIE severity.[26,28]
323

324 The proposed role of tau as a surrogate marker of fetal hypoxia is further evidenced by the
325 correlation between early cord blood BD-tau and non-reassuring fetal status observed in this
326 study. This finding was not statistically significant when adjusting for mode of delivery and
327 gestational age. However, operative delivery is commonly performed for fetal distress, and

328 adjusting for mode of delivery could therefore cause the association between BD-tau and
329 fetal distress to be underestimated. Fetal distress, indicated by pathological fetal heart rate
330 abnormalities, may signal early hypoxia compensation and correlate with neonatal acidosis,
331 low APGAR scores, NICU admission, and resuscitation.[13,29] However, CTG interpretation is
332 subjective, operator-dependent, and has low predictive value for long-term outcomes.[29]
333 Biomarkers like BD-tau could improve diagnostic specificity and guide interventions such as
334 therapeutic hypothermia. BD-tau may offer a more specific marker of neurological damage
335 compared current blood biomarkers.[18,26–28]
336
337 Our study also explored potential correlations between neonatal tau levels and antenatal
338 risk factors for adverse neurological outcomes. Macroscopic (e.g., cord knots, marginal cord
339 insertion) and microscopic (e.g., avascular villi) abnormalities in the 'placenta–brain axis'
340 can contribute to intrauterine growth restriction and increased susceptibility of the fetal
341 brain to injury during acute stress.[30,31] We observed increased pTau217 levels in participants
342 with histopathological placental abnormalities. Our findings should prompt further
343 investigation into whether excessive tau phosphorylation may be related to aberrant
344 placental function, indicating potential increased risk of neurological injury.
345
346 Microscopic placental changes may also occur as a consequence of pre-eclampsia (PET).[32]
347 Non-PET hypertensive disorders may show some similar microvascular changes to a lesser
348 unknown degree, manifesting in increased neonatal stroke risk.[32] Associations between
349 increased tau and hypertension should be further explored to identify patients with
350 microvascular placental changes who may be more vulnerable to physiologic stress and
351 sentinel intrapartum events.

352

353 Phosphorylated tau (pTau217) showed a positive correlation with gestational age but not
354 hypoxic markers. While tau phosphorylation is essential for neuronal function, excessive
355 phosphorylation may contribute to neuronal dysfunction.[33,34] In adults, pTau217 elevation
356 reflects blood-brain barrier disruption and protein aggregation rather than direct neuronal
357 injury.[33,34] It remains unclear whether high neonatal pTau217 signals abnormal neuronal
358 development or increased neuropathology risk. Further research is needed to clarify these
359 mechanisms and define threshold levels for clinical significance.

360

361 ## Strengths and limitations

362

363 This study is the first to distinguish between specific tau subtypes—rather than relying solely
364 on total tau levels—paving the way for more precise diagnosis and prognosis. Correlations
365 between BD-tau and surrogate markers of hypoxia form a strong foundation for future
366 research into the use of cord blood tau in birth asphyxia screening. The successful sample
367 collection and analysis, using validated assays, highlights the potential for tau cord blood
368 measurement to feasibly be incorporated into neonatal care in an Australian context.

369

370 Limitations of this study included the relatively small sample size, from a single centre. In
371 addition, the largely 'healthy' maternal cohort and short-term follow-up limited adverse
372 outcome data. Also, our study only included static biomarker measurement at time of
373 delivery, missing serial neonatal samples. Late serum tau rises have been linked to
374 neurodevelopmental issues at 1–2 years,[35] highlighting the need for further research on
375 serial tau measurements.

Conclusions

This study establishes BD-tau and pTau217 as potential biomarkers for fetal hypoxia and neurological vulnerability. BD-tau correlated with fetal distress, cord lactate, and pH, while phosphorylated tau levels linked to maternal hypertension and placental abnormalities. Larger, longitudinal studies are needed to validate these findings and explore the integration of tau biomarkers into neonatal screening tools.

Acknowledgements

HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research

(JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).

Conflicts of interest

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

Contribution of Authorship

RDS designed the study in consultation with BdV, KK, BM, FG, and HM. FG, HZ and KB supplied the assays and managed biofluid analysis. KK consulted hospital records for relevant cohort data. EP and TP conducted the statistical analysis. EP, FG, and TP drafted the manuscript. All authors provided critical feedback on the manuscript.

Ethics approval

Ethics approval was granted by the Sydney Local Health District Human Research and Ethics Committee (approval reference: 2022/ETH01100). Data were reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Funding

The work is supported by US National Institutes of Health (NIH) grant R01 AG063849-01 (RDS). NIH R01 grants are subject to external peer review for scientific quality, and priority score is based advisory council assessment. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, and the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme –

448 Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health
449 and Care Research University College London Hospitals Biomedical Research Centre, and the
450 UK Dementia Research Institute at UCL (UKDRI-1003).
451

452 # References

453

454 1. Gaulee P, Yang Z, Sura L, et al. Concentration of Serum Biomarkers of Brain Injury in
455 Neonates With a Low Cord pH With or Without Mild Hypoxic-Ischemic Encephalopathy.
456 *Front Neurol*. 2022;13:934755. doi:10.3389/fneur.2022.934755
457 2. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns
458 with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev*.
459 2013;2013(1):CD003311. doi:10.1002/14651858.CD003311.pub3
460 3. Leijser LM, Vein AA, Liauw L, Strauss T, Veen S, Wezel-Meijler G van. Prediction of short-
461 term neurological outcome in full-term neonates with hypoxic-ischaemic
462 encephalopathy based on combined use of electroencephalogram and neuro-imaging.
463 *Neuropediatrics*. 2007;38(5):219-227. doi:10.1055/s-2007-992815
464 4. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and
465 electroencephalographic study. *Arch Neurol*. 1976;33(10):696-705.
466 doi:10.1001/archneur.1976.00500100030012
467 5. Finder M, Boylan GB, Twomey D, Ahearne C, Murray DM, Hallberg B. Two-Year
468 Neurodevelopmental Outcomes After Mild Hypoxic Ischemic Encephalopathy in the Era
469 of Therapeutic Hypothermia. *JAMA Pediatr*. 2020;174(1):48.
470 doi:10.1001/jamapediatrics.2019.4011
471 6. Sarnat HB, Flores-Sarnat L, Fajardo C, Leijser LM, Wusthoff C, Mohammad K. Sarnat
472 Grading Scale for Neonatal Encephalopathy after 45 Years: An Update Proposal. *Pediatr*
473 *Neurol*. 2020;113:75-79. doi:10.1016/j.pediatrneurol.2020.08.014

474 7. Fiala M, Baumert M, Surmiak P, Walencka Z, Sodowska P. Umbilical markers of perinatal
475 hypoxia. *Ginekol Pol*. 2016;87(3):200-204. doi:10.17772/gp/60552
476 8. Gonzalez-Ortiz F, Dulewicz M, Ashton NJ, et al. Association of Serum Brain-Derived Tau
477 With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain
478 Injury. *JAMA Netw Open*. 2023;6(7):e2321554.
479 doi:10.1001/jamanetworkopen.2023.21554
480 9. Gundersen JK, Gonzalez-Ortiz F, Karikari T, et al. Clinical value of plasma brain-derived tau
481 and p-tau217 in acute ischemic stroke. *Cereb Circ - Cogn Behav*. 2024;6:100291.
482 doi:10.1016/j.cccb.2024.100291
483 10. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma
484 Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol*.
485 Published online January 22, 2024:e235319. doi:10.1001/jamaneurol.2023.5319
486 11. Rubenstein R, Chang B, Yue JK, et al. Comparing Plasma Phospho Tau, Total Tau, and
487 Phospho Tau–Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers.
488 *JAMA Neurol*. 2017;74(9):1063. doi:10.1001/jamaneurol.2017.0655
489 12. Gonzalez-Ortiz F, Turton M, Kac PR, et al. Brain-derived tau: a novel blood-based
490 biomarker for Alzheimer's disease-type neurodegeneration. *Brain*. 2023;146(3):1152-
491 1165. doi:10.1093/brain/awac407
492 13. Gonzalez-Ortiz F, Ferreira PCL, González-Escalante A, et al. A novel ultrasensitive assay
493 for plasma p-tau217: Performance in individuals with subjective cognitive decline and
494 early Alzheimer's disease. *Alzheimers Dement*. 2024;20(2):1239-1249.
495 doi:10.1002/alz.13525

496 14. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions:
497 Amsterdam Placental Workshop Group Consensus Statement. *Arch Pathol Lab Med*.
498 2016;140(7):698-713. doi:10.5858/arpa.2015-0225-CC
499 15. East CE, Leader LR, Sheehan P, Henshall NE, Colditz PB, Lau R. Intrapartum fetal scalp
500 lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate
501 trace. *Cochrane Database Syst Rev*. 2015;2015(5):CD006174.
502 doi:10.1002/14651858.CD006174.pub3
503 16. Fetal blood sampling in intrapartum care: SESLHD clinical procedure. Published online
504 2019.
505 17. New South Wales Ministry of Health. Heart rate monitoring guide. Published online
506 2018. https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=GL2018_025
507 18. Toorell H, Zetterberg H, Blennow K, Sävman K, Hagberg H. Increase of neuronal injury
508 markers Tau and neurofilament light proteins in umbilical blood after intrapartum
509 asphyxia. *J Matern Fetal Neonatal Med*. 2018;31(18):2468-2472.
510 doi:10.1080/14767058.2017.1344964
511 19. ANZCOR (Australian and New Zealand Committee on Resuscitation). Guideline 13.1 –
512 Introduction to Resuscitation of the Newborn. Published online 2024.
513 https://www.anzcor.org/home/neonatal-resuscitation/guideline-13-1-introduction-to-
514 resuscitation-of-the-newborn/
515 20. Zalcberg D, Kramer K, Payne E, et al. The association of umbilical cord blood
516 neurofilament light with non-reassuring fetal status: a prospective observational study.
517 Published online January 25, 2025. doi:10.1101/2025.01.23.25320706

518 21. Hernan M, Robins J. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC; 2020.
519 https://www.hsph.harvard.edu/miguel-hernan/wp-
520 content/uploads/sites/1268/2024/01/hernanrobins_WhatIf_2jan24.pdf
521 22. Meng X li, Rosenthal R, Rubin DB. Comparing correlated correlation coefficients. *Psychol*
522 *Bull*. 1992;111(1):172-175. doi:10.1037/0033-2909.111.1.172
523 23. World Health Organization. Low birth weight. Published online 2024. Accessed
524 September 19, 2024. https://www.who.int/data/nutrition/nlis/info/low-birth-
525 weight#:~:text=Low%20birth%20weight%20has%20been,2500%20grams%20(5.5%20po
526 unds).
527 24. Diedenhofen B, Musch J. cocor: a comprehensive solution for the statistical comparison
528 of correlations. *PloS One*. 2015;10(3):e0121945. doi:10.1371/journal.pone.0121945
529 25. Sachs M. plotROC: A Tool for Plotting ROC Curves. *J Stat Softw Code Snippets*.
530 2017;79(2):1-19. doi:doi:10.18637/jss.v079.c02
531 26. Wu H, Li Z, Yang X, Liu J, Wang W, Liu G. SBDPs and Tau proteins for diagnosis and
532 hypothermia therapy in neonatal hypoxic ischemic encephalopathy. *Exp Ther Med*.
533 2017;13(1):225-229. doi:10.3892/etm.2016.3911
534 27. Chavez-Valdez R, Miller S, Spahic H, et al. Therapeutic Hypothermia Modulates the
535 Relationships Between Indicators of Severity of Neonatal Hypoxic Ischemic
536 Encephalopathy and Serum Biomarkers. *Front Neurol*. 2021;12:748150.
537 doi:10.3389/fneur.2021.748150
538 28. Toorell H, Carlsson Y, Hallberg B, et al. Neuro-Specific and Immuno-Inflammatory
539 Biomarkers in Umbilical Cord Blood in Neonatal Hypoxic-Ischemic Encephalopathy.
540 *Neonatology*. Published online September 29, 2023:1-9. doi:10.1159/000533473

541 29. Jonsson M, Ågren J, Nordén-Lindeberg S, Ohlin A, Hanson U. Neonatal encephalopathy
542 and the association to asphyxia in labor. *Am J Obstet Gynecol*. 2014;211(6):667.e1-8.
543 doi:10.1016/j.ajog.2014.06.027
544 30. Penn AA, Wintermark P, Chalak LF, et al. Placental contribution to neonatal
545 encephalopathy. *Semin Fetal Neonatal Med*. 2021;26(4):101276.
546 doi:10.1016/j.siny.2021.101276
547 31. Fox A, Doyle E, Geary M, Hayes B. Placental pathology and neonatal encephalopathy. *Int*
548 *J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet*. 2023;160(1):22-27.
549 doi:10.1002/ijgo.14301
550 32. Mann JR, McDermott S, Pan C, Hardin JW. Maternal hypertension and intrapartum fever
551 are associated with increased risk of ischemic stroke during infancy. *Dev Med Child*
552 *Neurol*. 2013;55(1):58-64. doi:10.1111/j.1469-8749.2012.04409.x
553 33. Flavin WP, Hosseini H, Ruberti JW, Kavehpour HP, Giza CC, Prins ML. Traumatic brain
554 injury and the pathways to cerebral tau accumulation. *Front Neurol*. 2023;14:1239653.
555 doi:10.3389/fneur.2023.1239653
556 34. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-
557 tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*.
558 2020;324(8):772-781. doi:10.1001/jama.2020.12134
559 35. Juul SE, Voldal E, Comstock BA, et al. Association of High-Dose Erythropoietin With
560 Circulating Biomarkers and Neurodevelopmental Outcomes Among Neonates With
561 Hypoxic Ischemic Encephalopathy: A Secondary Analysis of the HEAL Randomized
562 Clinical Trial. *JAMA Netw Open*. 2023;6(7):e2322131.
563 doi:10.1001/jamanetworkopen.2023.22131
564

Figure Captions

Figure 1:

Receiver–operator curve (ROC) analysis of BD-tau, pH, base excess, and lactate in predicting binary non-reassuring fetal status. (A) ROC for the generalised linear model predicting non-reassuring fetal status and including the regressors: biomarker, mode of delivery, and gestational age. (B) ROC for the generalised linear model predicting non-reassuring fetal status and including the regressors: biomarker and mode of delivery. ROC for the biomarkers only, including (C) all births, (D) excluding preterm births, (E) excluding elective caesarean section, and (F) excluding elective CS and preterm birth.

Figure 2:

Correlation between BD-tau and pTau217 and fetal factors—birthweight, head circumference, and gestational age. Spearman correlation coefficients are shown. Red dot: elective Caesarean section (CS); blue dot: emergency CS; green dot: vaginal delivery.

Figure 3:

Correlation between tau and mode of delivery. A: Correlation between Log_{10} BD-tau and mode of delivery. Wilcoxon p-values are shown for comparisons between individual modes of delivery. B: Correlation between Log_{10} pTau217 and mode of delivery. Red dot: elective caesarean section (CS); blue dot: emergency CS; green dot: vaginal delivery.

588 Figure 4:

589 Correlation between cord blood biomarkers. Association of BD-tau with Neurofilament light

590 chain (NfL) (n=105), pH (n=104), base excess (n=94), and lactate (n=103); association of

591 pTau217 and NfL (n=106), pH (n=105), base excess (n=95), and lactate (n=104). Red dot:

592 elective caesarean section (CS); blue dot: emergency CS; green dot: vaginal delivery.


A: All births, predicted by model of biomarker + MOD + gestational age
AUC (95%CI) = 0.91 (0.85, 0.96)
AUC (95%CI) = 0.88 (0.82, 0.95)
AUC (95%CI) = 0.89 (0.82, 0.96)
AUC (95%CI) = 0.88 (0.81, 0.95)
B: All births, predicted by model of biomarker + MOD
AUC (95%CI) = 0.90 (0.84, 0.96)
AUC (95%CI) = 0.88 (0.80, 0.95)
AUC (95%CI) = 0.87 (0.79, 0.95)
AUC (95%CI) = 0.88 (0.81, 0.95)
C: All births, predicted by biomarker alone
AUC (95%CI) = 0.75 (0.62, 0.87)
AUC (95%CI) = 0.73 (0.60, 0.86)
AUC (95%CI) = 0.81 (0.69, 0.92)
AUC (95%CI) = 0.82 (0.73, 0.91)
D: Excluding preterm, predicted by biomarker alone
AUC (95%CI) = 0.78 (0.64, 0.92)
AUC (95%CI) = 0.75 (0.61, 0.89)
AUC (95%CI) = 0.87 (0.80, 0.95)
AUC (95%CI) = 0.84 (0.75, 0.93)
E: Excluding elective CS delivery, predicted by biomarker alone
AUC (95%CI) = 0.64 (0.48, 0.81)
AUC (95%CI) = 0.67 (0.51, 0.82)
AUC (95%CI) = 0.66 (0.49, 0.83)
AUC (95%CI) = 0.64 (0.48, 0.81)
F: Excluding elective CS + preterm, predicted by biomarker alone
AUC (95%CI) = 0.69 (0.51, 0.87)
AUC (95%CI) = 0.65 (0.48, 0.82)
AUC (95%CI) = 0.68 (0.50, 0.85)
AUC (95%CI) = 0.64 (0.46, 0.81)
Sensitivity
1 - Specificity
0.00
0.10
0.25
0.50
0.75
0.90
1.00
Biomarker
BD-tau
Cord pH
Base excess
Lactate


BD-tau
pTau217
Birthweight
Head circumference
Gestational age
ρ = −0.13, p = 0.19
ρ = −0.23, p = 0.019
ρ = −0.16, p = 0.098
ρ = −0.24, p = 0.016
ρ = −0.019, p = 0.85
ρ = −0.25, p = 0.0096
Log10 cord BD-tau
Log10 cord ptau-217
Birthweight (kg)
Head circumference (cm)
Gestational age (weeks)


A: BD-tau
Kruskal-Wallis, p = <0.001
0.22
1.2e-06
0.0051
Log10 cord BD-tau
2.4
2.0
1.6
Elective CS
Emergency CS
Vaginal
Delivery mode
B: ptau217
Kruskal-Wallis, p = 0.420
Log10 cord ptau217
1.2
0.8
0.4
Elective CS
Emergency CS
Vaginal
Delivery mode


BD-tau
pTau217
NfL
pH
Base excess
Lactate
ρ = 0.57, p < 0.001
ρ = 0.44, p < 0.001
ρ = −0.29, p = 0.003
ρ = 0.042, p = 0.671
ρ = −0.35, p < 0.001
ρ = 0.048, p = 0.643
ρ = 0.34, p < 0.001
ρ = 0.046, p = 0.645
Log10 cord BD-tau
Log10 cord ptau-217
Log10 cord NfL
Cord pH
Cord base excess
Cord lactate